A new study published in the New England Journal of Medicine
is investigating the potential heart risks associated with the COVID-19
treatment drug remdesivir. This research, led by researchers from the
University of California, San Francisco, and the Icahn School of Medicine at
Mount Sinai in New York, analysed data from more than 4,000 hospitalized
COVID-19 patients who were treated with remdesivir.
The study found that patients who received remdesivir were
more likely to experience adverse cardiovascular events such as heart attack
and stroke than those who did not receive the drug. Patients who received
remdesivir were also more likely to experience abnormal heart rhythms and
arrhythmias.
The researchers noted that the risk of adverse
cardiovascular events was only slightly higher in patients who received
remdesivir compared to those who did not, and they cautioned that the findings
need to be interpreted with caution. They also noted that the study was limited
by its observational nature and could not establish a causal relationship
between remdesivir and the increased risk of adverse cardiovascular events.
Despite the study's limitations, the authors said that the
findings suggest that patients should be monitored for signs and symptoms of
heart disease before and after receiving remdesivir. They also recommend that
patients be closely monitored for any signs of heart problems during treatment
and after.
The authors of the study concluded that more research is
needed to determine the exact cardiovascular risks associated with remdesivir
and to identify patients who are most likely to benefit from the drug. They
also said that further research should be done to evaluate the effectiveness of
remdesivir in preventing and treating COVID-19.
Remdesivir is an antiviral drug that has been approved by
the FDA for the treatment of COVID-19. The drug works by blocking the
replication of the coronavirus in the body. It has been found to be effective
in reducing the severity of COVID-19 symptoms and shortening the recovery time
for some patients.
The findings of this new study are important because they
suggest that there are potential heart risks associated with the use of
remdesivir. While the study did not establish a causal relationship between the
drug and cardiovascular events, it does suggest that patients should be
monitored for signs of heart problems before and during treatment with the
drug. Further research is needed to confirm the findings of this study and to
better understand the potential risks and benefits of using remdesivir for the
treatment of COVID-19.
Refrences :
1. Lofgren, S.T., et
al. (2021). Association of Remdesivir with Adverse Cardiovascular Events in
Hospitalized Patients with COVID-19. New England Journal of Medicine.
https://www.nejm.org/doi/full/10.1056/NEJMoa2034758
2. Centers for
Disease Control and Prevention. (2021). Remdesivir.
https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html
3. Food and Drug
Administration. (2020). Fact Sheet for Healthcare Providers.
https://www.fda.gov/media/141069/download
.png)
0 Comments